Skip to main content

Table 1 Clinical and demographic characteristics of the Charité cohort

From: Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients

 

dSSc

lSSc

SScSS

Overlap

UCTD

All

Number

96

113

4

51

16

280

Age in yearsa

54.5 (14.7)

63.0 (11.2)

52.5 (12.9)

51 (13.2)

55.5 (10.6)

58.0 (13.3)

Duration of RP in yearsa

5 (10.2)

9.5 (12.6)

12 (21.3)

7 (8.6)

8 (9.6)

7.5 (11.3)

Duration of disease in yearsa

5 (7.7)

8 (7.0)

3.5 (6.8)

7 (7.6)

5 (10.9)

7 (7.6)

Females/males

79/17

105/8

2/2

41/10

16/0

243/37

mRSSa

11.0 (9.61)

4.0 (4.3)

1.0 (1.1)

3.0 (6.9)

0.0 (1.1)

5.0 (8.0)

Digital ulcersb

52 (54.2)

38 (33.6)

2 (50)

18 (35.2)

2 (12.5)

112 (40.0)

Lung fibrosisb

57 (59.4)

16 (14.2)

3 (75)

20 (39.2)

2 (12.5)

98 (35.0)

DLCO-SBa, %

65.3 (21.9)

78.9 (17.5)

51.1(12.8)

71.2 (21.7)

80.0 (17.1)

72.4 (20.5)

Mean FVCa, %

82.1 (18.9)

97.4 (15.2)

95.5 (30.7)

86.5 (20.5)

95.2 (18.0)

91.6 (19.0)

Contracturesb

78 (81.3)

62 (54.9)

2 (50)

27 (52.9)

3 (18.8)

172 (61.4)

PAHb

22 (22.9)

22 (19.5)

2 (50)

13(25.7)

1 (6.3)

60 (21.4)

Renal involvementb

17 (17.7)

22 (19.5)

1 (25)

14 (27.5)

2 (12.5)

56 (20.0)

Renal crisisb

10 (10.4)

3 (2.7)

n = 112

1 (25)

1 (2.0)

1 (6.3)

16 (5.7)

n = 279

Cardiac involvementb

47 (49.0)

35 (31.0)

3 (75)

25 (49)

4 (25)

117 (40.7)

Skin involvementb

94 (98.9)

105 (92.9)

3 (75)

39 (76.5)

7 (43.8)

248 (88.9)

RPb

95 (99)

110 (97.3)

4 (100)

50 (98)

13 (81.3)

272 (97.1)

  1. aValues displayed are medians (standard deviations). bValues displayed are numbers of patients (percentages). DLCO-SB, predicted diffusion capacity of a single breath; dSSc, diffuse systemic sclerosis; FVC, forced vital capacity; lSSc, limited systemic sclerosis; mRSS, modified Rodnan skin score; PAH, pulmonary arterial hypertension; RP, Raynaud phenomenon; SScSS, systemic sclerosis sine scleroderma; UCTD, undifferentiated connective tissue disease.